专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US08569283B2 Compounds and compositions as c-Kit kinase inhibitors 有权
标题翻译：化合物和组合物作为c-Kit激酶抑制剂
公开(公告)号：US08569283B2
公开(公告)日：2013-10-29
申请号：US13598213
申请日：2012-08-29
申请人： Valentina Molteni , Hank Michael James Petrassi , Xiaolin Li , Xiaodong Liu , Jon Loren , Juliet Nabakka , Bao Nguyen , Vince Yeh
发明人： Valentina Molteni , Hank Michael James Petrassi , Xiaolin Li , Xiaodong Liu , Jon Loren , Juliet Nabakka , Bao Nguyen , Vince Yeh
IPC分类号： A61K31/437 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61P1/00 , A61P1/16 , A61P3/00 , A61P3/10 , A61P7/00 , A61P9/12 , A61P11/00 , A61P11/02 , A61P11/06 , A61P17/00 , A61P29/00 , A61P37/00 , A61P37/08 , C07D471/04 , C07D491/048 , C07D491/107
CPC分类号： C07D491/107 , C07D471/04 , C07D491/044 , C07D491/048 , C07D498/04
摘要： The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.
摘要翻译：本发明提供了可用作蛋白激酶抑制剂的化合物及其药物组合物，以及使用这些化合物治疗，改善或预防与异常或失调激酶活性相关的病症的方法。在一些实施方案中，本发明提供了使用这些化合物治疗，改善或预防涉及c-kit或c-kit和PDGFR（PDGFRα，PDGFRβ）激酶异常活化的疾病或病症的方法。

12. 发明授权

US08338417B2 Compounds and compositions as c-kit and PDGFR kinase inhibitors 失效
标题翻译：化合物和组合物作为c-kit和PDGFR激酶抑制剂
公开(公告)号：US08338417B2
公开(公告)日：2012-12-25
申请号：US12598922
申请日：2008-05-02
申请人： Xiaolin Li , Xiaodong Liu , Valentina Molteni , Donatella Chianelli , Jon Loren , Juliet Nabakka , Timothy Ramsey , Werner Breitenstein
发明人： Xiaolin Li , Xiaodong Liu , Valentina Molteni , Donatella Chianelli , Jon Loren , Juliet Nabakka , Timothy Ramsey , Werner Breitenstein
IPC分类号： C07D401/04 , C07D401/14 , A61K31/506
CPC分类号： C07D401/04 , C07D417/14
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFR and PDGFR kinases.
摘要翻译：本发明提供了一类新颖的化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法，特别是涉及c-kit，PDGFR异常活化的疾病或病症， PDGFR激酶。

13. 发明申请

US20110301175A1 5- (4- (HALOALKOXY) PHENYL) PYRIMIDINE-2-AMINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS 有权
标题翻译： 5-（4-（HALOALKOXY）苯基）嘧啶-2-胺化合物和作为激酶抑制剂的组合物
公开(公告)号：US20110301175A1
公开(公告)日：2011-12-08
申请号：US12674416
申请日：2008-08-19
申请人： Valentina Molteni , Xiaolin Li , Xiaodong Liu , Donatella Chianelli , Juliet Nabakka , Jon Loren , Shuli You
发明人： Valentina Molteni , Xiaolin Li , Xiaodong Liu , Donatella Chianelli , Juliet Nabakka , Jon Loren , Shuli You
IPC分类号： A61K31/506 , C07D401/12 , C07D403/12 , C07D413/12 , A61P9/12 , A61P11/06 , A61P17/00 , A61P1/00 , A61P35/00 , C07D239/42 , A61K31/505
CPC分类号： C07D239/42 , C07D401/12 , C07D403/12 , C07D413/12
摘要： The invention provides compounds of formula (1) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, AbI, BCR-AbI, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3. Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, Fms, KDR, c-rapor b-raf kinases.
摘要翻译：本发明提供了可用作蛋白激酶抑制剂的式（1）化合物及其药物组合物，以及使用这些化合物治疗，改善或预防与异常或失调激酶活性相关的病症的方法。在一些实施方案中，本发明提供了使用这些化合物治疗，改善或预防涉及c-kit，PDGFRα，PDGFR和bgr，CSF1R，AbI，BCR-AbI，CSK，JNK1，JNK2，p38异常活化的疾病或病症的方法，p70S6K，TGF＆bgr; SRC，EGFR，trkB，FGFR3。 Fes，Lck，Syk，RAF，MKK4，MKK6，SAPK2＆bgr; BRK，Fms，KDR，c-rapor b-raf激酶。

14. 发明授权

US07846949B2 Compounds and compositions as LXR modulators 有权
标题翻译：化合物和组合物作为LXR调节剂
公开(公告)号：US07846949B2
公开(公告)日：2010-12-07
申请号：US10589410
申请日：2005-02-11
申请人： Valentina Molteni , Xiaolin Li , Fang Liang , Juliet Nabakka , Enrique Saez , John Wityak
发明人： Valentina Molteni , Xiaolin Li , Fang Liang , Juliet Nabakka , Enrique Saez , John Wityak
IPC分类号： A61K31/44 , A61K31/42 , A61K31/41 , C07D213/55 , C07D498/00 , C07D231/12 , C07C229/00
CPC分类号： C07C233/83 , C07C237/38 , C07C237/42 , C07C239/20 , C07C255/29 , C07C255/54 , C07C255/60 , C07C271/28 , C07C311/08 , C07C317/22 , C07C323/42 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07D239/26
摘要： The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).
摘要翻译：本发明提供化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与肝脏X受体（LXR）活性相关的疾病或病症的方法。

15. 发明申请

US20100190811A1 PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS 失效
标题翻译：吡啶衍生物和组合物作为C-kit和PDGFR激酶抑制剂
公开(公告)号：US20100190811A1
公开(公告)日：2010-07-29
申请号：US12598919
申请日：2008-05-01
申请人： Xiaolin Li , Xiaodong Liu , Valentina Molteni
发明人： Xiaolin Li , Xiaodong Liu , Valentina Molteni
IPC分类号： A61K31/506 , C07D401/14 , A61P35/00 , A61P25/36 , A61P25/28 , A61P25/16 , A61P25/00 , A61P3/10 , A61P3/04 , A61P37/06 , A61P19/02
CPC分类号： C07D401/14 , C07D405/14
摘要： The invention provides a novel class of pyrimidine derivatives, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases.
摘要翻译：本发明提供了一类新颖的嘧啶衍生物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法，特别是涉及c-kit，PDGFRα异常活化的疾病或病症和PDGFR＆bgr; 激酶。

16. 发明授权

US07678792B2 Compositions and methods for modulating c-kit and PDGFR receptors 失效
标题翻译：用于调节c-kit和PDGFR受体的组合物和方法
公开(公告)号：US07678792B2
公开(公告)日：2010-03-16
申请号：US11873196
申请日：2007-10-16
申请人： Donatella Chianelli , Christopher Cow , Yun He , Songchun Jiang , Xiaolin Li , Xiaodong Liu , Zuosheng Liu , Jon Loren , Valentina Molteni , Juliet Nabakka , Pingda Ren , Taebo Sim , Xiaodong Wang , Shuli You
发明人： Donatella Chianelli , Christopher Cow , Yun He , Songchun Jiang , Xiaolin Li , Xiaodong Liu , Zuosheng Liu , Jon Loren , Valentina Molteni , Juliet Nabakka , Pingda Ren , Taebo Sim , Xiaodong Wang , Shuli You
IPC分类号： C07D471/04 , A61K31/4375 , A61K31/497 , A61K31/501 , A61K31/5355 , A61K31/506 , C07D413/14 , C07D213/69 , C07D213/61 , C07D213/74 , C07D213/80 , C07C205/06 , C07C301/00 , C07C255/07 , C07C69/73 , A61P17/10 , A61P29/00 , A61P3/10 , A61P31/00 , A61P27/14
CPC分类号： C07D471/04
摘要： The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.
摘要翻译：本发明提供了可用作蛋白激酶抑制剂的化合物及其药物组合物，以及使用这些化合物治疗，改善或预防与异常或失调激酶活性相关的病症的方法。在一些实施方案中，本发明提供了使用这些化合物治疗，改善或预防涉及c-kit，PDGFRα，PDGFR和bgr，CSF1R，Abl，BCR-Abl，CSK，JNK1，JNK2，p38异常活化的疾病或病症的方法，p70S6K，TGF-bgr，SRC，EGFR，trkB，FGFR3，FLT3，Fes，Lck，Syk，RAF，MKK4，MKK6，SAPK2＆bgr，BRK，KDR，c-raf或b-raf激酶或其突变形式。

17. 发明申请

US20100048539A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS 审中-公开
标题翻译：作为蛋白激酶抑制剂的化合物和组合物
公开(公告)号：US20100048539A1
公开(公告)日：2010-02-25
申请号：US12513498
申请日：2007-11-02
申请人： Donatella Chianelli , Xiaolin Li , Xiaodong Liu , Jon Loren , Valentina Molteni , Juliet Nabakka , Laszlo Revesz , Lawrence B. Perez , Clinton Brooks , Wojciech Wrona , Paul William Manley , Werner Breitenstein
发明人： Donatella Chianelli , Xiaolin Li , Xiaodong Liu , Jon Loren , Valentina Molteni , Juliet Nabakka , Laszlo Revesz , Lawrence B. Perez , Clinton Brooks , Wojciech Wrona , Paul William Manley , Werner Breitenstein
IPC分类号： A61K31/506 , C07D401/14 , C07D413/14 , C07D405/14 , A61K31/5377 , A61K31/538 , A61K31/55 , C12N5/00 , A61P35/00 , A61P37/00 , A61P3/00 , A61P25/00 , A61P9/00 , A61P37/08
CPC分类号： C07D401/14 , C07D401/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to beat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases. Formula (I).
摘要翻译：本发明提供了一类新颖的化合物，包含这些化合物的药物组合物和使用这些化合物来击败或预防与异常或失调的激酶活性相关的疾病或病症的方法，特别是涉及c-kit，PDGFRα异常活化的疾病或病症，以及 PDGFR＆bgr 激酶。式（I）。

18. 发明申请

US20090325981A1 Compounds and compositions as lxr modulators 失效
标题翻译：化合物和组合物作为lxr调节剂
公开(公告)号：US20090325981A1
公开(公告)日：2009-12-31
申请号：US10589087
申请日：2005-02-11
申请人： Valentina Molteni , Xiaolin Li , Juliet Nabakka , David Archer Ellis , Beth Anaclerio , Enrique Saez , John Wityak
发明人： Valentina Molteni , Xiaolin Li , Juliet Nabakka , David Archer Ellis , Beth Anaclerio , Enrique Saez , John Wityak
IPC分类号： A61K31/506 , C07D285/12 , A61K31/433 , A61K31/4439 , C07D417/04 , C07D417/12 , A61P3/00
CPC分类号： C07D285/12 , A61K31/433 , A61K31/4439 , A61K31/444 , A61K31/506 , A61K45/06 , C07D417/04 , C07D417/12 , C07D417/14
摘要： The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).
摘要翻译：本发明提供化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与肝脏X受体（LXR）活性相关的疾病或病症的方法。

19. 发明申请

US20080275804A1 Monte Carlo Grid Scheduling Algorithm Selection Optimization 失效
标题翻译：蒙特卡洛网格调度算法选择优化
公开(公告)号：US20080275804A1
公开(公告)日：2008-11-06
申请号：US12174755
申请日：2008-07-17
申请人： Viktors Berstis , Xiaolin Li
发明人： Viktors Berstis , Xiaolin Li
IPC分类号： G06Q10/00
CPC分类号： G06Q10/067 , G06Q10/0631 , G06Q40/00
摘要： A method for utilizing the Monte Carlo method to determine the most efficient arrangement of schedulers for a grid using a Scheduler Optimization Program (SOP). The SOP obtains the schedulers and scheduler timetable from memory and randomly selects a time period and scheduler to analyze. The SOP then uses the selected scheduler to modify the scheduler timetable. The SOP then runs the ROI calculator to obtain a ROI property for the modified timetable. If the ROI property for the modified timetable is greater than the ROI property for the original scheduler timetable, the SOP replaces the scheduler timetable with the modified timetable.
摘要翻译：一种使用蒙特卡罗方法来确定使用调度优化程序（SOP）的网格调度器的最有效布置的方法。 SOP从内存中获取调度器和调度器的时间表，并随机选择一个时间段和调度程序进行分析。然后，SOP使用所选择的调度程序来修改调度器时间表。 SOP然后运行ROI计算器以获得修改的时间表的ROI属性。如果修改时间表的ROI属性大于原始调度程序时间表的ROI属性，则SOP将使用修改的时间表替换调度程序时间表。

20. 发明授权

US09972988B2 Multi-functional direct current ice melting automatic switching circuit and switching method thereof 有权
公开(公告)号：US09972988B2
公开(公告)日：2018-05-15
申请号：US14357169
申请日：2012-05-21
申请人： Chuang Fu , Hong Rao , Shukai Xu , Xiaolin Li
发明人： Chuang Fu , Hong Rao , Shukai Xu , Xiaolin Li
IPC分类号： H02G7/16 , H02J3/02
CPC分类号： H02G7/16 , H02J3/02 , Y10T307/747
摘要： A multi-functional automatic switching circuit for direct current ice melting and a switching method thereof are provided. The automatic switching circuit comprises at least one sub-switching circuit. The sub-switching circuit comprises a six-pulse current converter (R) with no saturable reactor, six reactors (L1a, L1b, L1c, L2a, L2b, and L2c), three three-phase knife switches (Sac1, Sac2, and Sac3), and five single-phase knife switches (SV1, SV2, SV3, SV4, and SV5). The sub-switching circuits in series connection or parallel connection, four direct current side switching knife switches (Sdc1, Sdc2, Sdc3, and Sdc4), an isolation knife switch (K), a breaker (QF) and a control and protection system (CP) may form an automatic switching circuit for six-pulse or twelve-pulse direct current ice melting. The automatic switching circuit with no saturable reactor reduces noise during operation, achieves mutually automatic switching among modes of reactor switching, ice melting and test, and may complete the through-flow test of the automatic switching circuit without switching in a power transmission line, thereby solving the problem of daily operation and maintenance.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式